And here are more - from trading ViewCLSA – Rating UNDERPERFORM,...

And here are more - from trading View

CLSA – Rating UNDERPERFORM, Price Target $3.90

• Broker downgrades rating from OUTPERFORM and lowers price target from $4.00

Goldman Sachs – Rating SELL, Price Target $2.80

• Suggests Pilbara’s ability to capture recent improvement in the spodumene price is “likely limited” because around 90% of the company’s FY24 and FY25 production is committed to binding offtake agreements – which will result in a “small number of auctions”

• Notes that Pilbara’s net cash has nearly halved over the last six months to $1.4 billion in net cash. CAPEX and pricing challenges, plus already deferred non-essential spending, means the broker sees a prospect of a FY24 final dividend as “increasingly unlikely”

• Accounting for spending up to the end of Beyond P1000 expansion, net cash is expected to trough at around $800 million to $900 million

• Pilbara trades at a premium to its peers at 1.2 times net asset value (NAV) compared to its peer average of 1.05 times

JP Morgan – Rating UNDERWEIGHT, Price Target $3.10

• Cites valuation for downgrade in rating from NEUTRAL. Price target is lowered from $3.25

I read somewhere that Jardens have a target of $4.10 - cant find where I read it